Reimagine Care is using its own nurses and technology to help community oncology practices build programs for complex cancer therapies such as CAR-T and grow them without hiring n ...
Biosimilars can cost $600 a month versus $6,000 for branded rivals, but PBM rebate incentives push formularies toward pricier ...
Dan Nardi shares how Reimagine Care uses AI triage and connected devices to scale outpatient cancer support, enabling faster, personalized symptom monitoring. The newest wave of cancer therapies, ...
Lean MASLD/MASH comprises a meaningful subset of patients, with lean MASH linked to higher all-cause mortality and liver events despite lower cardiometabolic comorbidity than obese disease. Adding ...
A post-2018 16.8% rise in Hispanic HIV incidence in anti-sanctuary counties temporally aligned with public charge expansion to Medicaid, consistent with deterrence from prevention, testing, and ...
In this discussion, Ohio State economist Eric Seiber, Ph.D., explains how inconsistent claims-data definitions can skew ...
CMS’ mandatory GLOBE drug model ties some Medicare Part B rebates to global prices, but cuts projected savings sharply amid ...
Some predicted that drugmakers might boost launch prices to make up for Medicare drug negotiations shrinking profits. Harvard ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results